Since our inception, Phillips Ormonde Fitzpatrick (POF) has worked with clients around the world. While in the last century (and the one before!), we focused on our clients’ interests in Europe and America, the 21st century has seen greater focus on the Asian region as a driver of growth. In response to this growth, and …
>> Read more
The decision in Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254 continues the recent trend of owners of pharmaceutical patents obtaining interlocutory injunctions to prevent entry of generic products onto the Australian market.
A majority of the High Court has today held that methods of medical treatment may be patentable subject matter.
An Australian Intellectual Property Litigation Round-Up from the Commonwealth Courts portal for the week ending 29 November 2013.
An Australian Intellectual Property Litigation Round-Up from the Commonwealth Courts portal for the week ending 22 November 2013.
The Department of Industry has today released the Australian Innovation System Report 2013. The report aims to show trends and indicators in the Innovation System and the 2013 report focuses on Australia’s relationship with Asia.
Below is a report from IP Organisers (an independent service company of Phillips Ormonde Fitzpatrick) detailing Australian Pharmaceutical Patents which will expire in the next month.
The “Raising the Bar” amendments made substantial changes to the Patents Regulations 1991 (Cth) in so far as they relate to the conduct of patent oppositions including the regulations relevant to seeking an extension of time in which to file evidence. Under the previous regime, multiple extensions of time were routinely obtained. As the recent …
>> Read more
An Australian Intellectual Property Litigation Round-Up from the Commonwealth Courts portal for the week ending 15 November 2013.
An Australian Patent Opposition, Revocation and Extension of Term Round-Up from the Patent Office Journal dated 31 October – 14 November 2013. If you wish to oppose the grant of a patent, or if your grant own application has been opposed by third parties, please contact us.
